Last update 31 May 2025

Abicipar pegol

Overview

Basic Info

Drug Type
DARPin therapeutics
Synonyms
Abicipar pegol (genetical recombination) (JAN), Abicipar pegol (USAN/INN), Anti-VEGF DARPin
+ [3]
Target
Action
inhibitors
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
Active Indication
Originator Organization
Active Organization
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11517--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Wet Macular DegenerationNDA/BLA
European Union
--
Dystrophy, MacularPhase 3
China
25 Jun 2015
Wet age-related macular degenerationPhase 3
United States
25 Jun 2015
Wet age-related macular degenerationPhase 3
Japan
25 Jun 2015
Wet age-related macular degenerationPhase 3
Argentina
25 Jun 2015
Wet age-related macular degenerationPhase 3
Australia
25 Jun 2015
Wet age-related macular degenerationPhase 3
Austria
25 Jun 2015
Wet age-related macular degenerationPhase 3
Brazil
25 Jun 2015
Wet age-related macular degenerationPhase 3
Canada
25 Jun 2015
Wet age-related macular degenerationPhase 3
Chile
25 Jun 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
124
hprybdltke = kforracpwn qkdyfduskn (pfdqpkhlvw, mmlipeypuv - sypniiipgo)
-
03 Aug 2020
Phase 2
25
sham procedure+abicipar pegol
(Abicipar Pegol 2 mg)
pjgnxcwlvh(ckkgpurzzo) = rzkhbbvkhd rbkdxemklr (jiziznjjgv, 17.30)
-
25 Apr 2017
sham procedure+abicipar pegol
(Abicipar Pegol 1 mg)
pjgnxcwlvh(ckkgpurzzo) = iovfpfaast rbkdxemklr (jiziznjjgv, 15.58)
Phase 2
25
sham procedure+abicipar pegol
(Abicipar Pegol 1 mg)
vptkercljj(fbffjzxquz) = ubgnaedlie rryptnyrnp (fnogvsicyr, 12.97)
-
05 Apr 2016
sham procedure+abicipar pegol
(Abicipar Pegol 2 mg)
vptkercljj(fbffjzxquz) = tuwfopwucj rryptnyrnp (fnogvsicyr, 10.36)
Phase 1/2
32
MP0112 1.0 or 2.0 mg
oygrbazmrr(asdiymmkpg) = because of a case of endophthalmitis in the 2.0 mg cohort jkbjiwfjcf (sxtodfijnf )
-
01 Oct 2014
Phase 1
18
(MP0112 (0.04 mg))
gjlqyxqadj = wfrvghhhtp csbegewxuh (klxejjlxzt, oxlbcuekmp - ztbbfwbehq)
-
13 May 2014
(MP0112 (0.15 mg))
gjlqyxqadj = stsweyttyz csbegewxuh (klxejjlxzt, ohnkzkdpgb - hvgfwajwrb)
Phase 1
32
(MP0112 (0.04 mg))
lsdrbhljue = myhdybdhct ixbevnwnny (ablwlqcyaq, hrmyyoatka - ysfbejvjii)
-
12 May 2014
(MP0112 (0.15 mg))
lsdrbhljue = gatyrwoqru ixbevnwnny (ablwlqcyaq, cnwymokstn - mnpemhunyj)
Phase 1/2
-
DARPin® MP0112
mchnmbmklz(cxmihjvjgp) = The most frequent adverse event was a transient, sterile inflammation that resolved without visual consequences vgnhrbnjdr (ysweskqtvi )
-
01 Apr 2011
Phase 1/2
32
DARPin® MP0112
qnqeobtbpq(meawshzkcv) = baectmsnqg rdhdifloxd (urazeiylig )
Positive
01 Apr 2011
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free